Drugs / SFG-02
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07167914 | Sep 2025 → Apr 2026 | — | Juro Sciences Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SFG-02 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07167914 ↗ |
| Route | Other | “Transdermal Formulation (SFG-02)” NCT07167914 ↗ |